A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

LONDON (Reuters) -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in ...

Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), ...

There was a marked increased in the detection of illegal weight loss type medicines, as more than a million units of illegal ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...